Vaxart Announces Withdrawal of Reverse Stock Split Proposal

Core Viewpoint - Vaxart, Inc. has officially withdrawn its reverse stock split proposal and will focus on advancing its oral recombinant vaccine platform to create long-term value for stockholders [1][2]. Company Overview - Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines using a proprietary delivery platform that allows for storage and shipping without refrigeration [3]. - The company's vaccine candidates include those targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [3]. - Vaxart has filed broad domestic and international patent applications for its oral vaccination technology [3].